GSK launches six-part dollar bond to refinance Nuvalent buyout

This six-tranche dollar deal extends GSK's refinancing across the curve, locking in long-term funding for a major M&A outlay. The 30-year tranche's tight pricing relative to Treasuries signals strong investor appetite for investment-grade pharma credit, even amid rate uncertainty. For bond markets, the move underscores how large-cap acquirers are quickly replacing bridge loans with permanent capital, a pattern that may shape issuance supply. Watching whether the multi-currency strategy—euros followed by dollars—becomes a template for other buyout-funded issuers is the next focal point.